Arkgen Bioscions Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$6.54M
- Investors
-
15
Arkgen Bioscions General Information
Description
Developer of protein-based therapeutics designed for immuno-oncology purposes. The company's platform utilizes advanced biotechnology and a research and development framework to access cutting-edge treatments that target specific proteins, enabling the healthcare market to enhance immune response and offer potential improvements in patient outcomes for cancer therapy.
Contact Information
Website
www.arkgenbio.comCorporate Office
- Number 402-4, B4, 582 Daedeok-daero
- Okto Building, Yuseong-gu, Doryong-dong
- Daejeon
- South Korea
Corporate Office
- Number 402-4, B4, 582 Daedeok-daero
- Okto Building, Yuseong-gu, Doryong-dong
- Daejeon
- South Korea
Arkgen Bioscions Timeline
Arkgen Bioscions Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A) | 13-Jul-2026 | $6.54M | Completed | Generating Revenue | ||
| 3. Accelerator/Incubator | 30-Nov-2023 | Completed | Generating Revenue | |||
| 2. Seed Round | 05-Jul-2023 | $3.09M | $3.09M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Stealth |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Arkgen Bioscions Signals
Arkgen Bioscions Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Huons Global | Corporation | Minority | ||
| IBK Venture Investment | Corporate Venture Capital | Minority | ||
| IMM Investment | Asset Manager | Minority | ||
| Industrial Bank of Korea | PE/Buyout | Minority | ||
| Korea Credit Guarantee Fund | Venture Capital | Minority |
Arkgen Bioscions Investments (1)
Arkgen Bioscions’s most recent deal was a Corporate Asset Purchase with LG Chem (Global Development and Commercialization Rights of Anticancer Therapeutic Vaccine Platform). The deal was made on 18-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| LG Chem (Global Development and Commercialization Rights of Anticancer Therapeutic Vaccine Platform) | 18-Nov-2024 | Corporate Asset Purchase | Buildings and Property |
Arkgen Bioscions Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| LG Chem (Global Development and Commercialization Rights of Anticancer Therapeutic Vaccine Platform) | Seoul, South Korea |
Arkgen Bioscions FAQs
-
When was Arkgen Bioscions founded?
Arkgen Bioscions was founded in 2021.
-
Where is Arkgen Bioscions headquartered?
Arkgen Bioscions is headquartered in Daejeon, South Korea.
-
What is the size of Arkgen Bioscions?
Arkgen Bioscions has 12 total employees.
-
What industry is Arkgen Bioscions in?
Arkgen Bioscions’s primary industry is Drug Discovery.
-
Is Arkgen Bioscions a private or public company?
Arkgen Bioscions is a Private company.
-
What is Arkgen Bioscions’s current revenue?
The current revenue for Arkgen Bioscions is .
-
How much funding has Arkgen Bioscions raised over time?
Arkgen Bioscions has raised $9.6M.
-
Who are Arkgen Bioscions’s investors?
Huons Global, IBK Venture Investment, IMM Investment, Industrial Bank of Korea, and Korea Credit Guarantee Fund are 5 of 15 investors who have invested in Arkgen Bioscions.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process